Core Viewpoint - China Resources Boya Biopharmaceutical is divesting 80% of its subsidiary Jiangxi Boya Xinhao Pharmaceutical Co., Ltd. for 213 million yuan, indicating a strategic shift due to ongoing financial struggles and market pressures [1] Group 1: Financial Performance - In 2024, Boya Biopharmaceutical's revenue from blood products accounted for 87.29%, but overall revenue declined by 34.58% to 1.735 billion yuan, while net profit increased by 67.18% to 397 million yuan, still below 2022 levels [2] - The company’s plasma collection volume reached 630.6 tons in 2024, a mere 10.4% increase, leaving a significant gap of nearly 60% from its "14th Five-Year Plan" target of 1,000 tons [2] Group 2: Industry Dynamics - The blood product market in China is entering an oligopolistic phase, with the top six companies, including Tian Tan Biological and Shanghai Raist, controlling 80% of plasma collection [2] - Recent acquisitions, such as Shanghai Raist's 4.2 billion yuan purchase of Nanyue Biological, intensify competition, highlighting the challenges faced by Boya Biopharmaceutical in scaling its operations [3] Group 3: Strategic Challenges - The blood product industry has high barriers to entry, with a scarcity of licenses since 2001, making resource acquisition critical for growth [3] - Boya Biopharmaceutical's operational cash flow for 2024 is only 430 million yuan, raising concerns about its ability to compete in a market where acquisition costs are rising [3] Group 4: Future Outlook - The divestment of Boya Xinhao is expected to generate short-term liquidity of 213 million yuan and optimize the asset structure, but long-term growth relies on breakthroughs in the blood product sector [4] - The market anticipates that by 2027, the blood product market in China will reach 78 billion yuan, with a compound annual growth rate of 11.6%, presenting both opportunities and risks for Boya Biopharmaceutical [4]

截图来自天坛生物公告 公告内，天坛生物表示利润下滑的主要原因包括产品价格下降，尽管销量有所增长，但产品价格的下降导致利润减少幅度超过了销量增长对利润的贡献。此 外，血液制品市场竞争激烈，公司在销售模式和销售策略方面面临不确定性，导致利润水平受到波动影响。同时，成本的上升也可能对利润产生了一定的挤 压，使得公司在价格下降的同时，利润空间进一步缩小。 4月15日晚间，天坛生物发布2025年一季报显示，公司实现营业收入13.18亿元，同比增长7.84%，但归属于上市公司股东的净利润却出现了显著下滑，为 2.44亿元，同比下降22.90%；扣除非经常性损益后的归属于上市公司股东的净利润为2.39亿元，同比减少23.71%。 | 项目 | 本报告期 | 上年同期 | 增减 | | --- | --- | --- | --- | | 营业总收入 | 131,776.64 | 122, 195. 52 | | | 营业利润 | 40, 624. 71 | 51, 626. 39 | | | 利润总额 | 40, 627. 85 | 51, 622. 23 | | | 归属于上市公司股东的净利 润 | 24, 414. 57 ...

Core Viewpoint - Tian Tan Biological has experienced a decline in stock price over the past four trading days, with a cumulative drop of -5.57% [1] Company Overview - Beijing Tian Tan Biological Products Co., Ltd. was listed in 1998 and specializes in the research, manufacturing, sales, and consulting services of blood products [1] Shareholder Information - E Fund's E Fund CSI 300 Pharmaceutical ETF has entered the top ten shareholders of Tian Tan Biological, marking a new entry in the fourth quarter of last year [1] - The fund manager of E Fund's CSI 300 Pharmaceutical ETF is Yu Haiyan, who has extensive experience in investment management [4][5] Performance Metrics - The year-to-date return for the E Fund CSI 300 Pharmaceutical ETF is -3.41%, ranking 2040 out of 3440 in its category [1] - Recent performance metrics show a weekly increase of 0.84%, a monthly decrease of -4.94%, and a quarterly increase of 1.67% [2]

Financial Performance - Total revenue for Q1 2025 reached ¥131,776.64 million, an increase of 7.84% compared to ¥122,195.52 million in the same period last year[2] - Operating profit decreased by 21.31% to ¥40,624.71 million from ¥51,626.39 million year-on-year[2] - Net profit attributable to shareholders fell by 22.90% to ¥24,414.57 million, down from ¥31,667.40 million in the previous year[2] - Basic earnings per share decreased to ¥0.12, a decline of 22.90% from ¥0.16 in the same period last year[2] - The weighted average return on equity decreased by 1.00 percentage point to 2.17% from 3.17% year-on-year[2] Assets and Equity - Total assets increased by 2.31% to ¥1,623,534.38 million from ¥1,586,952.22 million at the beginning of the period[2] - Shareholders' equity attributable to the company rose by 2.19% to ¥1,138,285.00 million from ¥1,113,870.44 million[2] Strategic Plans - The company plans to enhance production and sales coordination and control costs to improve profitability[4] Market Conditions - The decline in profit was attributed to a greater decrease in product prices compared to the increase in sales volume[3][4] - The company does not foresee any uncertainties affecting the accuracy of this earnings report[5]

星标 ★ IPO日报 精彩文章第一时间推送 血制品行业整合并购再提速。 近期，上海莱士血液制品股份有限公司（002252.SZ）（下称"上海莱士"、"上市公司"）发布公告，拟以支付现金的方式，收购湖南血制品企业南岳生物 制药有限公司（下称"南岳生物"、"标的公司"）100%股权。 资料显示，上海莱士是我国目前营收规模最大的血制品企业，而南岳生物系湖南省唯一一家血液制品生产厂家，对于"得浆站者得天下"的血制品赛道，上 海莱士再下一城。 值得一提的是，去年6月，海尔集团斥资125亿元拿下上海莱士20%股权，此次是海尔集团入主上海莱士后发起的第一笔并购动作。 制图： 佘诗婕 一路"买买买" 近年来，血制品企业间并购整合不断，行业格局加速成型。 由于血制品是生物安全性极高的行业，2001年5月起，国家对血制品行业实行总量控制，不再批准新的生产企业，血制品行业呈现存量竞争的局面。 并且单采血浆站只能由血制品企业设立，且在一个采浆区域内仅可设置一个单采血浆站，新建浆站的平均获批周期长达18至24个月。 对比新建浆站需要投入的人力物力，企业往往倾向于选择"买买买"的外延并购方式，以实现快速扩张。 2024年8月，天坛生物通 ...

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][50]. Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16]. - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points, ranking 22nd among 31 sub-industries [19][24]. Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective and human-relevant methods, which could enhance drug safety and lower costs [14][15]. - The shift is anticipated to accelerate drug development timelines and improve success rates, particularly benefiting companies involved in AI drug development such as Jingtai Holdings and Chengdu Xian Dao [6][17]. Subsector Performance - The blood products sector saw the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline at 16.04% [7][23]. - The medical device sector decreased by 2.62%, and the traditional Chinese medicine sector fell by 3.35% [7][23]. Recommended and Benefiting Stocks - Recommended stocks include Weidian Physiotherapy, Maipu Medical, and Yingke Medical [8][31]. - Benefiting stocks from the FDA policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17]. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from the "old-for-new" policy and increased procurement activities in Q2 2025, with a current P/E ratio of 32.15, indicating potential for valuation growth [27][29]. - **Medical Consumables**: This sector is under pressure due to US-China tariff impacts, but certain segments are expected to perform well due to high growth potential and improved conditions [30]. - **IVD Sector**: The IVD sector is projected to recover as AI technologies enhance diagnostic capabilities, despite current pressures from procurement policies [33]. - **Blood Products**: The sector is expected to benefit from rising domestic production and increased focus on local sourcing due to tariff impacts [35]. - **Retail Pharmacy**: The offline pharmacy sector is seeing a recovery in customer traffic and profitability, with major players expected to leverage AI for operational efficiency [37][38].

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The FDA's recent decision to gradually eliminate animal testing requirements for monoclonal antibodies and other drugs is expected to benefit AI-driven drug development, potentially accelerating new drug approvals and reducing R&D costs [5][6][14][16] - The pharmaceutical and biotechnology sector experienced a decline of 5.61% this week, underperforming the CSI 300 index by 2.73 percentage points [19][24] - The blood products sector showed the highest increase this week, rising by 4.06%, while the medical outsourcing sector faced the largest decline, dropping by 16.04% [7][19][23] Summary by Sections Weekly Insights - The FDA's announcement on April 11, 2025, aims to replace animal testing with more effective human-relevant methods in drug development, which could enhance drug safety and lower costs [14][15] - The pharmaceutical sector's performance this week was marked by significant declines across various sub-sectors, with blood products being the only one to gain [19][23] Sub-sector Performance - Blood products increased by 4.06%, while medical outsourcing fell by 16.04%, indicating a significant divergence in performance among sub-sectors [7][19][23] - The medical device sector's P/E ratio is currently at 32.15, suggesting potential for valuation increases [27] - The IVD sector is also seen as having room for valuation growth, with a current P/E of 21.89 [33] Recommended and Benefiting Stocks - Recommended stocks include Microelectrophysiology, Maipu Medical, and Yingke Medical, among others [8][31][38] - Benefiting stocks from the FDA's policy change include Jingtai Holdings, Chengdu Xian Dao, and Hongbo Pharmaceutical [6][17] Market Trends - The report highlights a structural investment opportunity in the pharmaceutical sector, driven by policy support and AI-enabled R&D [26] - The report notes that the medical device sector is expected to benefit from upcoming procurement policies and a low base effect in Q2 2025 [27][29]

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Views - The report emphasizes the ongoing disruptions caused by the US-China tariff policies and suggests focusing on opportunities in non-US markets and import substitution [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, while companies primarily exporting to markets outside the US will be less affected [4][9] Summary by Sections Tariff Policy Overview - Since April 2, 2025, the US government has imposed a 34% "reciprocal tariff" on Chinese goods, with frequent adjustments to tariff rates and exemptions for certain pharmaceutical products [4][5] - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [5] Opportunities in the Biopharmaceutical Sector - The report identifies potential for domestic products to increase market share in the blood products sector due to tariff impacts, particularly for albumin, where US imports are significant [9] - It suggests monitoring companies such as Palin Bio, Tiantan Bio, and Huashan Bio for potential growth in market share as import costs rise [9] Medical Devices - The report notes that the tariff policies and anti-dumping investigations are likely to accelerate the domestic substitution process in medical devices, particularly in electrophysiology and imaging fields [10] - Companies like Yirui Technology and United Imaging are highlighted as making progress in domestic production capabilities [10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumption recovery" as key investment themes [12] - Specific companies to watch include BeiGene, Mindray, and Xiamen Innovax for their innovative products and overseas market potential [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, demonstrating strong cash flow and reduced losses [13][14] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products and a strong pipeline [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - **Wuxi Biologics**: Recognized for its strong technical capabilities and expanding overseas operations [22] Market Performance - The report notes a decline in the pharmaceutical sector, with a 5.61% drop in the past week, while the overall market saw a smaller decline [31][42] - The biopharmaceutical sector is highlighted as having the smallest decline among sub-sectors, indicating relative resilience [44]

Investment Rating - The industry investment rating is "Outperform the Market" [52] Core Viewpoints - The ongoing US-China tariff policies are causing disruptions, suggesting a focus on non-US market expansion and import substitution opportunities in the biopharmaceutical sector [4][9] - The report highlights that the adjustment of tariffs is expected to impact the trade of pharmaceutical products between China and the US, with companies primarily exporting to markets outside the US being less affected [4][9] - The report emphasizes the potential for domestic products to gain market share in the biopharmaceutical sector due to increased tariffs on US imports [9][10] Summary by Sections Tariff Policy Overview - As of April 11, 2025, the tariff rates for bilateral trade between China and the US have been adjusted to 125%, with China indicating it will not respond to further tariff increases from the US [4][5] Biopharmaceutical Sector Insights - The blood products sector is expected to stabilize prices and increase the market share of domestic products due to tariff impacts on imports, particularly for albumin [9] - The medical device sector is anticipated to accelerate domestic substitution due to reliance on North American production, with specific focus on electrophysiology and imaging products [10] - The report suggests monitoring companies such as Palin Bio, Tian Tan Bio, and Huashan Bio for potential growth opportunities in the blood products market [9][10] Investment Strategies - The report recommends focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [12] - Specific companies highlighted for innovation include BeiGene, Dongcheng Pharmaceutical, and others with strong global competitiveness [12] - Companies like Mindray Medical and United Imaging are noted for their potential in overseas markets [12] Key Companies to Watch - Notable companies include: - **Nocera Biopharma**: Expected to achieve significant revenue growth with its core product, showing a 49% year-on-year increase in sales [13] - **Sino Biopharmaceutical**: Rapid revenue growth with a focus on innovative products [18] - **Kexing Biopharma**: Stable domestic business with promising overseas expansion [18] - The report also highlights the potential of companies like East China Pharmaceutical and others in the nuclear medicine sector [17] Market Performance - The biopharmaceutical sector has seen a decline of 5.61% recently, with specific sub-sectors experiencing varying levels of impact [31][44]

证券研究报告 | 医药生物 | 2025年4月12日 www.hczq.com 华创医药投资观点&研究专题周周谈·第121期 海外CXO 2024财报总结 本周周专题联系人：万梦蝶 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号: S0360523080008 邮箱: wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱 ...